The Safety Problem With Patches And How (Nasdaq: NTRB) Plans To Address It

The room at Nasdaq MarketSite in New York

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored The Safety Problem With Patches And How (Nasdaq: NTRB) Plans To Address It *Get Our Updates Faster—Tap Here To Receive SMS Alerts* September 25th Greetings, Friend! The room at Nasdaq MarketSite in New York is built for companies with something to say. On September 16th, one of them was a small developer with a big idea about pain patches. Nutriband Inc. (Nasdaq: NTRB) announced that company CEO Gareth Sheridan would attend the inaugural Nasdaq LaB Biotech Summit, an evening bringing together biotechnology executives, market participants, and industry leaders. It's a fitting stage. The company's pitch sits at the crossroads of two powerful themes: better pain management and the fight against o-pioid misuse. Here's the tension. Prescription fent-a-nyl patches help patients with severe chronic pain. But a patch can be tampered with, diverted, or accidentally touched. Nutriband's answer isn't pulling the patch. It's re-engineering it. Its AVERSA technology incorporates aversive agents into transdermal patches to deter abuse, diversion, misuse, and accidental exposure, while keeping these therapies available to the patients who need them. That technology is covered by patents issued in 46 countries. Source: Nutriband press release (Sep. 8th, 2026); Annual Shareholder Meeting Update (Jan. 2026) And the product is picking up a public identity. In March, Nutriband selected a worldwide commercial brand name candidate for its patch, developed with branding specialist Brand Institute. By September, those trademarks had reached the USPTO publication stage. Company Breakdown: Nutriband Inc. Headquartered in Orlando, Florida, Nutriband Inc. develops transdermal pharmaceutical products. Its lead candidate is an abuse-deterrent fent-a-nyl patch built on AVERSA. Development partner Kindeva is incorporating AVERSA into its own FDA-approved transdermal fent-a-nyl patch system. The platform isn't limited to one product. The company says AVERSA can be applied to medications with abuse potential, including o-pioids and stimulants. A second segment, Active Intelligence, is a wholly owned subsidiary focused on wellness, recovery, and performance consumer products. More Report Sources: NTRB Website. Behind The Scenes: The Annual Meeting Roadmap In January, Nutriband laid out its playbook to shareholders. At its January 24th, 2026, Annual Shareholder Meeting, the company added two new directors: Alessandro Puddu, an Italian Chartered Accountant, and Viorica Carlig, a senior executive with service-sector leadership experience. The 2026 plan was even more telling. Management said it intended to file a nonprovisional patent application that could extend AVERSA product protection to 2046, manufacture clinical supplies for Human Abuse Liability trials, and file an IND. It also reviewed 2025 milestones, including a strengthened Kindeva partnership, completed commercial manufacturing scale-up, and a Type C meeting with the FDA. The Shift: Building A Commercial Footprint Nutriband is no longer only a development story. It's laying commercial rails. In March, the company's AI Kinesiology Tapes were approved for distribution and sale in Costa Rica. That followed an exclusive agreement with Costa Rica's Innomedica to distribute the fent-a-nyl patch upon approval, along with all sports tape products. Stateside, Active Intelligence took its AI-branded portfolio to the June ECRM conference to meet with teams from Walmart, Walgreens, Amazon, and Cardinal Health. New launches included AI Performance Tape, AI Energy Patches, and AI Sleep. 910,904 NTRB Warrants Face A No-Extension Deadline Here's a detail on Nutriband that's easy to miss: The Warrants: 910,904 outstanding from the 2021 IPO. The Price: A $6.43 exercise price. The Deadline: September 30th, 2026. The Terms: No extension, no repricing, no modification. The company's message is simple. Exercise before the deadline, or the warrants are gone. That could be a notable cleanup event for NTRB. A potential source of dilution that's hung over the share structure for years is finally reaching its end. What could be left behind? A potentially cleaner capital structure. 7 Potential Catalysts Send (Nasdaq: NTRB) To The Top Of Our Watchlist #1. Executive Visibility At The Inaugural Nasdaq LaB Biotech Summit. A seat at this event puts (NTRB) in front of biotech leaders and market participants in New York. #2. A Potential Patent Filing Could Extend Protection To 2046. The planned nonprovisional application could potentially lengthen the runway for (NTRB) and its AVERSA products. #3. A Streamlined Regulatory Pathway With One Pivotal Study. Under 505(b)(2), the NDA for (NTRB) would rest primarily on a single Phase 1 abuse potential study. #4. Commercial Brand Trademarks Advancing Toward A Notice Of Allowance. Clearing the opposition window would potentially let (NTRB) move its brand name into FDA labeling review. #5. A Slew Of Bullish Technical Indicators Appear Triggered At Barchart. When the closing bell rang Thursday, Barchart was reporting (NTRB) to have 12 of 13 key technical indicators triggered across terms including the website’s composite “Trend Seeker” indicator flashing as well. #6. International Distribution Groundwork Already Signed In Costa Rica. The Innomedica agreement gives (NTRB) a ready partner for both its patch and sports tapes. #7. A Tightly Held Share Structure With Low Float Characteristics. At approx. 5.28Mn shares in its float according to Yahoo Finance, (NTRB) fits a low float idea, meaning the potential for heightened volatility may be significant. Closing Thoughts Nutriband Inc. (Nasdaq: NTRB) is working on a problem with real public health weight, and it's doing it methodically: patents in 46 countries, a regulatory plan built on one pivotal study, trademarks in motion, and a consumer arm meeting national retailers. The pieces are visible. The next milestones are named. We’re kicking-off coverage on Nutriband Inc. (Nasdaq: NTRB). Stay tuned for updates heading your way soon. Talk again shortly. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 09/24/2026 and ending on 09/28/2026 to publicly disseminate information about (NTRB:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid fifty one thousand five hundred USD ("Funds"). These Funds were part of the one hundred thirty four thousand USD funds that TD Media LLC received from Nutriband Inc., the issuer of (NTRB:US). Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (NTRB:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/ntrb-elb0m/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Constant Contact Data Notice